Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy
A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis
A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis
Differing formulations and ratios of the subjects’ medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.
Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.
Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.
The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.
The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.
This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.
Cognitive impairment is common in patients with multiple sclerosis (MS) and considerably impacts quality of life.
Alemtuzumab is associated with reduced magnetic resonance imaging disease activity and the slowing of brain volume loss over 7 years in patients with relapsing-remitting multiple sclerosis.
Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.